Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Vicus Therapeutics has commenced VT-122, a novel investigational combination of etodolac and propranolol, and Nexavar (sorafenib) tablets randomized, open label, multi-center Phase 2 clinical trial as a treatment option for patients with advanced liver cancer (hepatocellular carcinoma), systemic inflammation and cachexia.
Subscribe to our email newsletter
The Phase 2 trial will investigate whether VT-122 in combination with Nexavar increases ‘Clinical Benefit Response,’ which is a composite measurement of pain, performance status, and lean body mass, as compared to Nexavar alone.
The secondary efficacy endpoints of this study are cancer and cachexia specific symptoms, duration of Nexavar therapy and overall survival.
The trail is expected to recruit around 80 patients with advanced liver cancer, systemic inflammation and cachexia at multiple sites in the US.